General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Bayer(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT), Medtronics(MODEST), Roche(MODEST), Vifor(SIGNIFICANT), LivaNova(MODEST), FIRE1(NONE), Abbott Laboratories(MODEST), Eli Lilly and Company(SIGNIFICANT), CVRx(SIGNIFICANT), Occlutech(MODEST), American Regent(MODEST), Pfizer(MODEST), Applied Therapeutics(MODEST), Cardiac Dimension(MODEST), Edwards(SIGNIFICANT), Element Sciences(SIGNIFICANT), Imbira(MODEST), Innolife(MODEST), Lexicon(MODEST), Pharmacosmos(MODEST), Sequanna(SIGNIFICANT), SQ Innovation(MODEST), Tricog(MODEST), Cardior(MODEST), Tenex(MODEST), AstraZeneca Pharmaceuticals(SIGNIFICANT), Cytokinetics(MODEST), Daxor(NONE), Impulse Dynamics(SIGNIFICANT), Inventiva(MODEST), Novartis(MODEST), Novo Nordisk Inc.(SIGNIFICANT) SPEAKER'S BUREAU: Novartis Corporation(MODEST) EQUITY INTERESTS/STOCK OPTIONS: PharmaIn(NONE) OTHER FINANCIAL BENEFIT: Medscape(SIGNIFICANT), G3 Pharmaceutical(NONE)

View Full Disclosure